156 related articles for article (PubMed ID: 37069537)
1. Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration.
Nassisi M; Pozzo Giuffrida F; Milella P; Ganci S; Aretti A; Mainetti C; Dell'Arti L; Mapelli C; Viola F
BMC Ophthalmol; 2023 Apr; 23(1):156. PubMed ID: 37069537
[TBL] [Abstract][Full Text] [Related]
2. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
[TBL] [Abstract][Full Text] [Related]
3. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.
Stattin M; Haas AM; Ahmed D; Graf A; Krepler K; Ansari-Shahrezaei S
Eur J Ophthalmol; 2022 Jul; 32(4):2312-2318. PubMed ID: 34726553
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
6. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol.
Sevik MO; Aykut A; Özkan G; Dericioğlu V; Şahin Ö
Int Ophthalmol; 2021 Sep; 41(9):2951-2961. PubMed ID: 33864577
[TBL] [Abstract][Full Text] [Related]
7. The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens.
Jiang B; Gao L; Dong S; Hou Q; Sun M; Zhang J; Yu H; Zhang Z; Sun D
Adv Ther; 2022 Apr; 39(4):1568-1581. PubMed ID: 34817809
[TBL] [Abstract][Full Text] [Related]
8. IMPACT study: Impact of adherence to anti-VEGF intravitreal injections for macular disease during COVID 19-related confinement in France.
Hurand V; Ducloyer JB; Baudin F; Aho S; Weber M; Kodjikian L; Devin F; Gabrielle PH; Creuzot-Garcher C; Massin P;
Acta Ophthalmol; 2023 Feb; 101(1):91-99. PubMed ID: 35765939
[TBL] [Abstract][Full Text] [Related]
9. IMPACT OF COVID-19 PANDEMIC LOCKDOWNS ON VISUAL ACUITY OF PATIENTS WITH NEOVASCULAR AMD: A Large Cohort.
Shor R; Segal O; Mimouni M; Greenbaum E; Zur D; Trivizki O; Schwartz S; Loewenstein A; Goldstein M; Rabina G
Retina; 2022 Aug; 42(8):1529-1535. PubMed ID: 35502974
[TBL] [Abstract][Full Text] [Related]
10. Ten-year survival trends of neovascular age-related macular degeneration at first presentation.
Arpa C; Khalid H; Chandra S; Wagner S; Fasler K; Faes L; Pooprasert P; Chopra R; Moraes G; Balaskas K; Keane PA; Sivaprasad S; Fu DJ
Br J Ophthalmol; 2021 Dec; 105(12):1688-1695. PubMed ID: 33011683
[TBL] [Abstract][Full Text] [Related]
11. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
12. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic.
Borrelli E; Grosso D; Vella G; Sacconi R; Battista M; Querques L; Zucchiatti I; Prascina F; Bandello F; Querques G
Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2621-2628. PubMed ID: 33009973
[TBL] [Abstract][Full Text] [Related]
13. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis.
Im JHB; Jin YP; Chow R; Dharia RS; Yan P
Surv Ophthalmol; 2022; 67(6):1593-1602. PubMed ID: 35970234
[TBL] [Abstract][Full Text] [Related]
14. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
[TBL] [Abstract][Full Text] [Related]
15. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic.
Stepanov A; Nemcansky J; Veith M; Manethova K; Stredova M; Pencak M; Tarkova A; Studnicka J
Eur J Ophthalmol; 2021 Sep; 31(5):2488-2495. PubMed ID: 33198503
[TBL] [Abstract][Full Text] [Related]
16. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment.
Yeter DY; Dursun D; Bozali E; Ozec AV; Erdogan H
J Fr Ophtalmol; 2021 Mar; 44(3):299-306. PubMed ID: 33608176
[TBL] [Abstract][Full Text] [Related]
17. Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: A single-centre French study.
Wolff B; Macioce V; Vasseur V; Castelnovo L; Michel G; Nguyen V; Daien V; Mauget-Faÿsse M; Gillies M
Clin Exp Ophthalmol; 2020 Jul; 48(5):636-643. PubMed ID: 32112667
[TBL] [Abstract][Full Text] [Related]
18. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
[TBL] [Abstract][Full Text] [Related]
20. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
